Brakewood Harold Eugene 4
4 · Immuneering Corp · Filed May 23, 2024
Insider Transaction Report
Form 4
Immuneering CorpIMRX
Brakewood Harold Eugene
Chief Business Officer
Transactions
- Award
Stock Option
2024-05-21+165,000→ 165,000 totalExercise: $3.01Exp: 2033-03-31→ Class A Common Stock (165,000 underlying) - Disposition to Issuer
Stock Option
2024-05-21−165,000→ 0 totalExercise: $9.71Exp: 2033-03-31→ Class A Common Stock (165,000 underlying) - Disposition to Issuer
Stock Option
2024-05-21−60,500→ 0 totalExercise: $6.09Exp: 2034-02-08→ Class A Common Stock (60,500 underlying) - Award
Stock Option
2024-05-21+60,500→ 60,500 totalExercise: $3.01Exp: 2034-02-08→ Class A Common Stock (60,500 underlying)
Footnotes (3)
- [F1]On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]The option vests and becomes exercisable as to 25% of the underlying shares on January 23, 2024 and then in equal monthly installments over the subsequent three years, subject to Mr. Brakewood's continued employment through each applicable vesting date.
- [F3]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028.